BARCELONA, Spain—(UPDATED) Aspirin has long been the antiplatelet of choice for long-term secondary prevention in patients with coronary disease, but a meta-analysis of several trials suggests P2Y12 ...

Aspirin continues to be underused as a means of secondary prevention, particularly in countries with low per capita incomes but also in wealthier nations, a new analysis shows. The study combined data ...

A polypill that includes key medications associated with improved outcomes (aspirin, angiotensin-converting–enzyme [ACE] inhibitor, and statin) has been proposed as a simple approach to the secondary ...

Research presented at the 2024 European Society of Cardiology Congress explored gender-based care and outcomes disparities, with potential implications for health care policy and equitable care of ...

Please provide your email address to receive an email when new articles are posted on . Many people requiring secondary prevention drugs for CVD do not receive them. This trend persisted even in ...